CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

secretin human

Trade name: chirhostim

PeptideapprovedOrphan Drug FDA

Approved

Apr 4, 2002

Secretin is a hormone that regulates water homeostasis throughout the body and influences the environment of the duodenum by regulating secretions in the stomach, pancreas, and liver. It is a peptide hormone produced in the S cells of the duodenum, which are located in the intestinal glands. In humans, the secretin peptide is encoded by the SCT gene. — Wikipedia

Clinical trial activity

32 trials · 25 clinical orgs · 2 marketing orgs

Phase 1
9
Phase 2
16
Phase 3
10
Phase 4
4

Earliest trial started Jun 1, 1999 (NCT00065962)

Timeline

1990s

  1. Jan 1, 1999

    Earliest Phase 3 Sponsor(trial)

  2. Jun 16, 1999

    Orphan Drug Designation

2000s

  1. Apr 4, 2002

    Earliest FDA Approval

  2. Apr 9, 2004

    ChiRhoClin, Inc. — NDA Secondary Org

  3. Jan 1, 2005

    Earliest Phase 2 Sponsor(trial)

  4. Jan 1, 2006

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedApr 4, 2002

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](C(N)=O)C(C)C
Mol. weight
3039.46 g/mol
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • chirhostim
  • chirhostim
  • chirhostim
  • human secretin
  • human secretin
  • human secretin
  • human secretin
  • human secretin
  • human secretin
  • human secretin
  • secreflo
  • secreflo
  • secretin
  • secretin
  • secretin
  • secretin
  • secretin
  • secretin
  • secretin
  • secretin-ferring
  • secretin-ferring
  • secretin human
  • secretin human
  • secretin (human)
  • secretin (human)
  • secretin (human)
  • secretin-kabi
  • secretin-kabi
  • secretin (swine), 15-l-glutamic acid-16-glycine-
  • secretin synthetic human
  • secretin synthetic human
  • secretin synthetic human
  • secretin synthetic human
  • secretin synthetic porcine
  • secretin synthetic porcine
  • secretin synthetic porcine
  • synthetic human secretin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07285863Phase 4Jan 31, 2026ChiRhoClin, Inc., Mayo Clinic
NCT05914077Phase 3Sep 13, 2023University of Barcelona
NCT05659147Phase 4Dec 31, 2022National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Cincinnati
NCT04613700N/AMar 1, 2020Steno Diabetes Center Copenhagen, University of Copenhagen
NCT04231279Phase 3Jan 31, 2020ChiRhoClin, Inc., Orlando Health
NCT03686618Phase 2Oct 1, 2018ChiRhoClin, Inc., Dartmouth University
NCT03617861Phase 1/Phase 2 (Phase 2)Sep 3, 2018Mayo Clinic
NCT03263481Phase 4Sep 1, 2017Indiana University
NCT02869893N/AAug 10, 2016ChiRhoClin, Inc., The National Pancreas Foundation, University of Cincinnati
NCT03290846Phase 2/Phase 3 (Phase 3)Aug 2, 2016Technical University of Munich, University of Turku
NCT02160808Phase 3May 1, 2014Dartmouth University
NCT02000089Phase 3Jan 6, 2014ChiRhoClin, Inc., Johns Hopkins University, National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT02458118Phase 1/Phase 2 (Phase 2)Jun 1, 2012University of Nottingham
NCT01094600N/AJun 1, 2012Columbia University
NCT01371240Early Phase 1 (Phase 1)Jun 1, 2011Case Western Reserve University, Repligen Corporation
NCT01265875Phase 1/Phase 2 (Phase 2)Dec 1, 2010ChiRhoClin, Inc., Dartmouth University
NCT01452217Phase 1Sep 1, 2010University of Nottingham
NCT01094626N/AApr 1, 2010Columbia University
NCT01134848Phase 4Jan 1, 2009University of Nottingham
NCT00660335Phase 3Mar 1, 2008Repligen Corporation
Showing 20 of 32 trials
Page 1 / 2

Organizations

Research & Development (25)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ChiRhoClin, Inc.For profit8342006
Repligen CorporationFor profit6332002
Columbia UniversityAcademic/Hospital4412006
Dartmouth UniversityAcademic/Hospital3122010
Harvard UniversityAcademic/Hospital3312008
Indiana UniversityAcademic/Hospital3322005
Mayo ClinicAcademic/Hospital3322006
University of NottinghamAcademic/Hospital3332009
National Institutes of Health (NIH)Government2111999
University of CincinnatiAcademic/Hospital2222016
Case Western Reserve UniversityAcademic/Hospital1112011
Johns Hopkins UniversityAcademic/Hospital1112014
National Cancer Institute (NCI)Government1012014
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Government1012022
National Institute on Deafness and Other Communication Disorders (NIDCD)Government1011999
Orlando HealthAcademic/Hospital1112020
Steno Diabetes Center CopenhagenAcademic/Hospital1112020
St. Louis UniversityAcademic/Hospital1012007
Technical University of MunichAcademic/Hospital1012016
The National Pancreas FoundationAcademic/Hospital1012016
25 organizations
Page 1 / 2

Marketing (2)

OrganizationOrg typeRelationshipDate
ChiRhoClin, Inc.For profitNDA2Apr 9, 2004
FerringFor profitNDA—